Sangamo gets RMAT status for its hemophilia gene therapy
On July 5 Sangamo Therapeutics (SGMO) and partner Pfizer (PFE) announced update results of a Phase 1/2 study of Sangamo's SB-525 gene therapy for severe hemophilia A. The companies also announced that the U.S. Food & Drug Administration had granted regenerative...
Bonus Dividend Pick for my Volatility Portfolio–DOW, a cash cow with a 5.5% yield
Today, June 28, I added Corteva (CTVA), one of the three stocks to emerge from the merger, reorganization, and then breakup of Dow and DuPont, to my Volatility Portfolio. Â . On Monday, Â I'll be adding another from that breakup to my Volatility Portfolio. This time...
No. 2 Value Pick Constellation Brands up 4.73% today on earnings
On June 26 I added Constellation Brands (STZ), my No. 2 pick in my 5 Best Value Picks Special Report to my Volatility Portfolio. Today, June 28, Constellation Brands closed 4.73% higher on final first quarter earnings. Revenue grew 2.4% year over year. (The company's...
Adding Corteva, #8 in my 10 Best Picks for the Rest of 2019, to my Volatility Portfolio
Last night I added seed and agricultural chemicals company Corteva (CTVA) to my 10 Best Picks for the Rest of 2019 Special Report. Tomorrow June 28, I'll add it to my Volatility Portfolio. Confusion is your friend when you're looking for a stock that the market has...
Bonus Special Report: 5 Value Stocks in a Market Near All-Time Highs
The Standard & Poor's 500 closed at a new all-time high on June 20 at 2954.18. It's easy in today's market to find stocks trading at astronomical price to earnings ratios. Amazon (AMZN) sell for 79.90 times trailing twelve-month earnings per share. Netflix (NFLX)...
Adding Nektar call options to my Volatility Portfolio–again
Again. I'm adding the January 17, 2020 Call Options with a strike at $35 on Nektar Theraeutics (NKTR) to my Volatility Portfolio on JubakAM.com and JugglingWithKnives.com. (Ticker on these options is NKTR200117C00035000.) The underlying shares closed at $33.70, up...
Further lowering China exposure in my portfolios
This morning Wall Street is buzzing with talk that the U.S.-China trade war could stretch on to 2035. I think there's just about no chance of that. But we aren't looking at the quick resolution of the dispute that seemed possible just 10 days ago. And we are looking...
The Great (short-term) China Boom debate
Everybody seems to agree that things are looking up for the Chinese economy. The real disagreement is about how long this improvement might last and whether there's any chance that the upturn might go from improvement to boom. Here's some of the data that points to an...
Copper meeting bullish on projected supply deficit
The big Cesco copper conference in Santiago, Chile, has been remarkably bullish considering worries about global economic growth and the Chinese economy. That's because there looks like a significant gap in the development of new supplies in 2019 and 2020 that could...
After the market close, Boeing CEO announces that company will cut production by ten 737 planes a month.
By mid-April Boeing (BA) will cut production of its 737 plans to 42 a month from the current 52-a month pace. Before the crash of a 737 Max operated by Lion Air and one operated by Ethiopia Airlines, Boeing had planned to increase production of the 737 by 10% by...Making Nektar #8 on my list of 10 most dangerous stocks for earnings season–and #4 on my list of 5 to buy on any plunge
Nektar Therapeutics (NKTR) won't miss Wall Street earnings projections when it reports its first quarter financial results on May 9--because the company won't report any earnings. The consensus projection now has the company reporting a loss of 76 cents a share on...Jim’s Stock Alerts
Download Jim’s eBook for Free
